The Section of Pulmonary, Critical Care, and Sleep Medicine at Baylor College of Medicine is nationally recognized for its excellence in healthcare, research and education.

The section has total research support of $4.8 million from federal and private research grants including lung cancer, asthma, COPD, pulmonary hypertension, pulmonary fibrosis, transitional medicine, lung transplant, and cystic fibrosis.

Many physicians from the section are national and international experts. Together, they offer an incredibly large array of services, from general pulmonary and sleep medicine to highly specialized advanced lung diseases, such as including pulmonary hypertension, pulmonary fibrosis, adult cystic fibrosis, COPD/asthma, interstitial lung disease, lung and heart-lung transplantation, critical care, and interventional pulmonology.

The section offers four fellowship programs, including Pulmonary & Critical Care, Critical Care Medicine, Lung Transplantation, and Sleep Medicine. Many alumni and former fellows can be found in academic, research and healthcare leadership roles.

News

Baylor Genetics rebrand makes debut with simplified name, targeted messageYesterday
Baylor Miraca Genetics Laboratories, a joint venture of Baylor College of Medicine and Miraca Holdings, Inc., has rebranded as Baylor Genetics.
NASA, Baylor team up to discover new ways to protect astronautsJul 21, 2016
A grant for as much as $246 million will help develop the NASA Transitional Research Institute, which is focused on long-duration space flight missions.
Some muscle soreness normal after workoutJul 20, 2016
Sports medicine expert Dr. Theodore Shybut offers advice on what’s normal and what’s not when it comes to soreness after exercise.
Tips help manage skin in dry or humid weatherJul 19, 2016
Baylor College of Medicine expert Dr. Harry Dao shares some tips on how to keep skin skin during periods of dry or humid heat.
T cells that target two tumor surface molecules mitigate tumor escape in mouse model of glioblastomaJul 18, 2016
Researchers show a new strategy, based on targeting specific surface molecules, that eliminates most of the cancer cells in a mouse model of glioblastoma.